449 related articles for article (PubMed ID: 33260918)
1. Inositols in PCOS.
Kamenov Z; Gateva A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260918
[TBL] [Abstract][Full Text] [Related]
2. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
3. Inositol for subfertile women with polycystic ovary syndrome.
Showell MG; Mackenzie-Proctor R; Jordan V; Hodgson R; Farquhar C
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012378. PubMed ID: 30570133
[TBL] [Abstract][Full Text] [Related]
4. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
5. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
[No Abstract] [Full Text] [Related]
6. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
Wojciechowska A; Osowski A; Jóźwik M; Górecki R; Rynkiewicz A; Wojtkiewicz J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752081
[TBL] [Abstract][Full Text] [Related]
7. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
Sortino MA; Salomone S; Carruba MO; Drago F
Front Pharmacol; 2017; 8():341. PubMed ID: 28642705
[TBL] [Abstract][Full Text] [Related]
8. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
10. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
11. The relevance of inositols treatment for PCOS before and during ART.
Artini PG; Malacarne E; Tomatis V; Genazzani AD
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4799-4809. PubMed ID: 34337729
[TBL] [Abstract][Full Text] [Related]
12. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
13. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART).
Facchinetti F; Espinola MSB; Dewailly D; Ozay AC; Prapas N; Vazquez-Levin M; Wdowiak A; Unfer V;
Trends Endocrinol Metab; 2020 Aug; 31(8):570-579. PubMed ID: 32418772
[TBL] [Abstract][Full Text] [Related]
14. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
Gateva A; Unfer V; Kamenov Z
Gynecol Endocrinol; 2018 Jul; 34(7):545-550. PubMed ID: 29309199
[TBL] [Abstract][Full Text] [Related]
15. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Galletta M; Grasso S; Vaiarelli A; Roseff SJ
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
[TBL] [Abstract][Full Text] [Related]
16. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future.
Laganà AS; Myers SH; Forte G; Naem A; Krentel H; Allahqoli L; Alkatout I; Unfer V
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):61-72. PubMed ID: 38226638
[TBL] [Abstract][Full Text] [Related]
17. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
18. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
19. Inositols in the ovaries: activities and potential therapeutic applications.
Laganà AS; Forte G; Bizzarri M; Kamenov ZA; Bianco B; Kaya C; Gitas G; Alkatout I; Terzic M; Unfer V
Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):123-133. PubMed ID: 35472446
[TBL] [Abstract][Full Text] [Related]
20. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
